Julia Brandts
Overview
Explore the profile of Julia Brandts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brandts J, Muller-Wieland D
Curr Atheroscler Rep
. 2025 Jan;
27(1):24.
PMID: 39775321
Purpose Of Review: This review explores the relationship between lipid-lowering therapies, particularly statins, and the risk of new-onset diabetes (NOD). It examines the underlying mechanisms and evaluates whether other lipid-lowering...
2.
Stevens C, Vallejo-Vaz A, Chora J, Barkas F, Brandts J, Mahani A, et al.
J Am Heart Assoc
. 2024 Jun;
13(12):e034434.
PMID: 38879446
Background: Familial hypercholesterolemia (FH), while highly prevalent, is a significantly underdiagnosed monogenic disorder. Improved detection could reduce the large number of cardiovascular events attributable to poor case finding. We aimed...
3.
Closs K, Verket M, Muller-Wieland D, Marx N, Schuett K, Jost E, et al.
Digit Health
. 2024 Mar;
10:20552076241233998.
PMID: 38481796
Objective: This review aims to systematically map and categorize the current state of wearable applications among oncology patients and to identify determinants impeding clinical implementation. Methods: A Medline, Embase and...
4.
Brandts J, Tittel S, Bramlage P, Danne T, Brix J, Zimny S, et al.
Diabetes Obes Metab
. 2023 Sep;
25(12):3700-3708.
PMID: 37694759
Aim: To assess the implementation of the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guideline recommendations for lipid-lowering therapies among more than 30 000 patients with type 1...
5.
Brandts J, Bray S, Villa G, Catapano A, Poulter N, Vallejo-Vaz A, et al.
Lancet Reg Health Eur
. 2023 Aug;
31:100665.
PMID: 37547279
Background: The impact of the stepwise implementation of the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) treatment algorithm on low-density lipoprotein cholesterol (LDL-C) goal attainment was simulated in...
6.
Jacobsen M, Gholamipoor R, Dembek T, Rottmann P, Verket M, Brandts J, et al.
NPJ Digit Med
. 2023 Jun;
6(1):105.
PMID: 37268734
Serious clinical complications (SCC; CTCAE grade ≥ 3) occur frequently in patients treated for hematological malignancies. Early diagnosis and treatment of SCC are essential to improve outcomes. Here we report...
7.
Steiner B, Neumann A, Pelz Y, Ski C, Hill L, Thompson D, et al.
Eur J Public Health
. 2023 May;
33(3):448-454.
PMID: 37164632
Background: In Europe, more than 15 million people live with heart failure (HF). It imposes an enormous social, organizational and economic burden. As a reaction to impending impact on healthcare...
8.
Brandts J, Ray K
Nat Rev Cardiol
. 2023 Apr;
20(9):600-616.
PMID: 37055535
Lowering the levels of LDL cholesterol in the plasma has been shown to reduce the risk of atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as triglyceride-rich lipoproteins, HDL and...
9.
Brandts J, Verket M, Muller-Wieland D
Herz
. 2022 Aug;
47(5):419-425.
PMID: 36018378
Low-density lipoprotein (LDL) cholesterol (LDL-C) is a causal risk factor for cardiovascular complications. A target value is set according to risk, guideline-based and individual basis. We now have the means...
10.
Dinges S, Krotz J, Gass F, Treitschke J, Fegers-Wustrow I, Geisberger M, et al.
Diab Vasc Dis Res
. 2022 Aug;
19(4):14791641221113781.
PMID: 35953083
Background: Lifestyle interventions are a cornerstone in the treatment of chronic ischaemic heart disease (CIHD) and type 2 diabetes mellitus (T2DM). This study aimed at identifying differences in clinical characteristics...